- Home
- CZR vs BLTE Comparison
CZR vs BLTE Comparison
Compare CZR & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CZR | BLTE |
|---|---|---|
| Founded | 1937 | 2018 |
| Country | United States | United States |
| Employees | 15500 | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.0B |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CZR | BLTE |
|---|---|---|
| Price | $29.69 | $154.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | $31.92 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 3.5M | 143.2K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,473,504,000.00 | N/A |
| Revenue This Year | $3.56 | N/A |
| Revenue Next Year | $2.48 | $492.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 65.03 | N/A |
| 52 Week Low | $17.86 | $63.51 |
| 52 Week High | $30.88 | $200.00 |
Technical Indicators
Market Signals| Indicator | CZR | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 48.03 | 47.41 |
| Support Level | $29.52 | $146.94 |
| Resistance Level | $30.86 | $161.17 |
| Average True Range (ATR) | 0.12 | 6.60 |
| MACD | -0.01 | -1.53 |
| Stochastic Oscillator | 33.85 | 23.07 |
Price Performance
Historical ComparisonAbout CZR Caesars Entertainment Inc.
Caesars Entertainment's stand-alone portfolio includes about 50 domestic gaming properties across the Las Vegas (48% of 2025 EBITDAR) and regional (49%) markets. Additionally, the company hosts managed properties and digital assets that produced marginal EBITDA in 2025. Caesars' US presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the US portion of William Hill (it sold the international operation in 2022), a digital sports betting platform. The portfolio is set to expand to more than 60 casinos with the proposed acquisition of Caesars by Fertitta Entertainment and its Golden Nugget resorts.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.